EANS-Adhoc: Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae

ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.

11.02.2010

» Initial results from a first-in-man Phase I study indicate safety and immunogenicity of the Streptococcus pneumoniae vaccine candidate

Vienna (Austria), February 11, 2010 - Intercell AG (VSE: "ICLL") today announced results from a Phase I clinical trial investigating the company's vaccine candidate for the prevention of infections by the bacterium Streptococcus pneumoniae. Intercell's investigational prophylactic vaccine candidate (IC47) is a recombinant subunit vaccine consisting of three highly conserved proteins of Streptococcus pneumoniae.

In the first-in-man trial, 32 healthy adults were vaccinated with Intercell's investigational vaccine. Two antigen dosages, with and without addition of aluminum hydroxide, were applied in four different study groups.

The initial analysis of the data has indicated a good safety and tolerability of the vaccine candidate, which was confirmed by a Data Safety Monitoring Board. The vaccine was immunogenic, and antigen dose-dependent induction of antibodies was confirmed for all three proteins of the vaccine.

"We are pleased that we have been able to generate first-in-man data for a further vaccine candidate based on antigens discovered through our Antigen Identification Program (AIP®). Subject to clearance with the authorities and our partners, we next intend to initiate clinical development in two target populations - children and the elderly," stated Thomas Lingelbach, Intercell's Chief Operating Officer.

About Streptococcus pneumoniae infections

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations for developing pneumococcal infections. Annually, according to the World Health Organization, the bacterium kills up to one million children under the age of five years worldwide. It accounts for many bacterial Meningitis cases in adults, is the most common cause of Pneumonia, and also causes Bacteremia, Meningitis, and Otitis media in young children.

About Intercell's Streptococcus pneumoniae vaccine

The Company´s vaccine candidate is a recombinant subunit vaccine consisting of three conserved surface proteins from Streptococcus pneumoniae. Two of these proteins were discovered using Intercell's proprietary Antigen Identification Program (AIP®), while the third was in-licensed from the U.S. Centers for Disease Control and Prevention (CDC).
The development of Intercell's vaccine to prevent pneumococcal disease is supported by PATH, an international global health non-profit organization.

end of announcement euro adhoc

issuer: Intercell AG Campus Vienna Biocenter 3 A-1030 Wien phone: +43 1 20620-0 FAX: +43 1 20620-800 mail: investors@intercell.com WWW: www.intercell.com sector: Biotechnology ISIN: AT0000612601 indexes: ATX Prime, ATX

stockmarkets: official market: Wien
language: English

Digitale Pressemappe: http://www.ots.at/pressemappe/116

Rückfragen & Kontakt:

Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB0001